Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

million, respectively, in the same periods in 2012. The increases in 2013 compared to 2012 were due to an increase in revenue earned through the Company's strategic collaboration with Teva, as a result of the clinical development activities associated with the AFFINITY trial that was initiated in August 2012.
  • Total operating expenses for the three and nine months ended September 30, 2013 increased to $20.5 million and $49.6 million, respectively, compared to $14.9 million and $30.1 million, respectively, in the same periods in 2012. The increases in 2013 compared to 2012 were due primarily to increased clinical trial expenses associated with patient enrollment and treatment in the AFFINITY and Borealis-1 trials, increased costs related to the investigator-sponsored trials, increased employee expenses due to an increase in the number of employees to support our clinical development activities and increased toxicology expenses related to apatorsen and OGX-225.  These increases were partially offset by lower manufacturing costs due to the timing of apatorsen manufacturing activities.
  • Net loss for the three and nine months ended September 30, 2013 was $10.1 million, or $0.68 per diluted common share, and $25.2 million, or $1.72 per diluted common share, respectively. Net loss for the three and nine months ended September 30, 2012 was $5.9 million, or $0.40 per diluted common share, and $17.0 million, or $1.29 per diluted common share, respectively. The net loss in the nine months ended September 30, 2013 included a non-cash gain on revaluation of the warrant liability of $2.9 million compared with $2.5 million in the nine months ended September 30, 2012. 
  • The Company had $46.8 million in cash, cash equivalents and short-term investments as of September 30, 2013, compared to $75.4 million as of December 31, 2012.
  • 2013 cash guidance:
  • Net cash requirements are expected to be in the range of $40 - $50 million.

  • '/>"/>
    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
    3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
    4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... , Sept. 23, 2014 /PRNewswire/ - Portage Biotech Inc. ... Exchange: PBT.U), is pleased to announce that its ... added two more  consultants to its team for ... uses a new proprietary cell permeable peptide platform ... anti-inflammatory cargo into the eye. ...
    (Date:9/23/2014)... 23, 2014 Equashield ( ...     Devices  (CSTD) for hazardous drugs, ... Medical Technology Corporation.  Equashield,s leading CSTD has been ... , China and ... to expand globally, and throughout the ...
    (Date:9/23/2014)... September 23, 2014 Healthcare ... globe will convene at the Society for ... be held October 26-28 in Houston, Texas ... and practice in individualized integrative cancer care. ... nurses, psychologists, nutritionists, naturopaths, acupuncturists, and other ...
    (Date:9/22/2014)... Pearl's Premium Ultra Low Maintenance Lawn Seed ... seed this week with the release of their Pearl's ... the fact that it is time to plant now ... , As of the date 6/4/13, Pearl's Premium had ... experts and the media including: The National Gardeners ...
    Breaking Biology Technology:Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2
    ... to 26 in Kansas City. , ... Rockville, MD ... Annual Scientific Meeting (ASM) will be held in Kansas City, Mo., ... with the USP experts responsible for establishing internationally recognized standards for ...
    ... 3 ESA Biosciences, a Magellan,Biosciences company and ... for pharmaceutical development and QA/QC, life science, and,analytical-chemistry ... Frost & Sullivan North American Technology Innovation Award ... Sullivan will present the,award to ESA,s Vice President ...
    ... HOUSTON, Sept. 3 US Oncology Specialty, LP, ... the Occupational Excellence Achievement Award from the National,Safety ... award is presented to companies who produce the ... To be eligible, organizations must report,days away from ...
    Cached Biology Technology:USP's 2008 Annual Scientific Meeting to Convene Scientific Experts from Around the World 2USP's 2008 Annual Scientific Meeting to Convene Scientific Experts from Around the World 3ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems 2ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems 3US Oncology Pharmaceutical Distribution Service Wins National Safety Council Award 2
    (Date:9/22/2014)... that after a long stay in the Intensive Care ... remain behind in patients, intestines. The team tested these ... when provoked by conditions that mimic the body,s stress ... mBio , the online open-access journal of the American ... treatment of ICU patients who can develop a life-threatening ...
    (Date:9/22/2014)... cut grass in recent years has been identified as ... says the aroma also summons beneficial insects to the ... plant signals the environment via the emission of volatile ... for parasitic wasps to come to the plant that ... insect," said Dr. Michael Kolomiets, Texas A&M AgriLife Research ...
    (Date:9/22/2014)... Scientists have discovered a key molecular cog in a ... of circadian (daily) rhythms based on temperature. , Transcription ... based on external stresses such as light, rain, ... team of researchers at USC has isolated one, called ... here and there as needed while in keeping it ...
    Breaking Biology News(10 mins):Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3Genetic switch regulates a plant's internal clock based on temperature 2
    ... January 14, 2013 Using an innovative approach, scientists ... structure of Ltn1, a recently discovered "quality-control" protein that ... and animals. Ltn1 appears to be essential ... also be relevant to human neurodegenerative diseases, for an ...
    ... 2013Taking a vitamin D supplement and drinking cow,s milk are ... D is in a child,s body, new research has found. ... colour and exposure to the sun, according to Dr. Jonathon ... "Early childhood is a critical stage in human development, so ...
    ... is Everywhere" tenet of bacterial distribution in the ocean, ... "bipolar" species of bacteria that occur in the Arctic ... they found even fewer bipolar species than would turn ... everywhere. "That suggests that there are forces that are ...
    Cached Biology News:Scientists discover structure of protein essential for quality control, nerve function 2Scientists discover structure of protein essential for quality control, nerve function 3Supplements and cow's milk play biggest roles in determining vitamin D levels in children 2MBL scientists find 'bipolar' marine bacteria, refuting 'everything is everywhere' idea 2MBL scientists find 'bipolar' marine bacteria, refuting 'everything is everywhere' idea 3
    ... to MKK6 (phospho S207) ( Abpromise ... Antigen: Synthetic phosphopeptide ... phosphorylation site of Serine 207 (V-D-S ... Gene ID: 5608 ...
    Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
    CD45/CD34 combination 50 tests...
    XPC Immunogen: XPC (NP_004619, 141 a.a. ~ 251 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Biology Products: